Get the Stockscreener App
13.06
0.23%
-0.03
Compass Pathways Plc Adr stock is traded at $13.06, with a volume of 2.23M.
It is down -0.23% in the last 24 hours and down -12.23% over the past month.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
See More
Previous Close:
$13.09
Open:
$13.2
24h Volume:
2.23M
Relative Volume:
0.65
Market Cap:
$1.81B
Revenue:
-
Net Income/Loss:
$-191.97M
P/E Ratio:
-4.1362
EPS:
-3.1575
Net Cash Flow:
$-159.63M
1W Performance:
-14.02%
1M Performance:
-12.23%
6M Performance:
+132.38%
1Y Performance:
+130.74%
1-Day Range:
$13.03
$13.45
1-Week Range:
$12.95
$15.55
52-Week Range:
$4.88
$15.87
Compass Pathways Plc Adr Stock (CMPS) Company Profile
Name
Compass Pathways Plc Adr
Sector
Industry
Phone
1-716-676-6461
Address
3RD FLOOR, 1 ASHLEY ROAD, CHESIRE
Compare CMPS vs HCA, THC, EHC, FMS, DVA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPS
Compass Pathways Plc Adr
|
13.06 | 1.81B | 0 | -191.97M | -159.63M | -3.1575 |
HCA
Hca Healthcare Inc
|
435.61 | 94.31B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
259.71 | 20.91B | 21.46B | 2.65B | 3.35B | 19.23 |
EHC
Encompass Health Corp
|
123.47 | 12.18B | 6.07B | 793.80M | 464.40M | 5.9914 |
FMS
Fresenius Medical Care Ag Adr
|
22.69 | 12.08B | 22.44B | 1.35B | 2.03B | 1.9002 |
DVA
Davita Inc
|
178.47 | 11.39B | 13.84B | 1.10B | 1.49B | 10.42 |
Compass Pathways Plc Adr Stock (CMPS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | B. Riley Securities | Buy |
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-23-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-27-25 | Initiated | Stifel | Buy |
| Jul-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-01-24 | Initiated | Morgan Stanley | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-22 | Resumed | Berenberg | Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Oct-29-21 | Initiated | Oppenheimer | Outperform |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
| May-11-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-01-21 | Initiated | ROTH Capital | Buy |
| Oct-14-20 | Initiated | H.C. Wainwright | Buy |
| Oct-13-20 | Initiated | Berenberg | Buy |
| Oct-13-20 | Initiated | Canaccord Genuity | Buy |
| Oct-13-20 | Initiated | Cowen | Outperform |
| Oct-13-20 | Initiated | Evercore ISI | Outperform |
View All
Compass Pathways Plc Adr Stock (CMPS) Latest News
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch - Yahoo Finance
COMPASS Pathways at TD Cowen summit: launch prep meets regulatory risk - Investing.com India
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data - Yahoo Finance
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances - Yahoo Finance
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression - Yahoo Finance
Fluence to develop psilocybin therapy training for Compass - investing.com
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training - Finviz
Compass Pathways Forecast: Breakout Could Target $22.51–$25.51 - FXEmpire
Compass Pathfinder Limited: Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year - FinanzNachrichten.de
Compass Pathways stock hits 52-week high at 15.4 USD - investing.com
Compass Pathways stock shows durable results in depression trial - investing.com
COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question - sahmcapital.com
Compass Pathways Target of Unusually High Options Trading (NASDAQ:CMPS) - MarketBeat
How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions - Sahm
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances - Yahoo Finance
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
COMPASS Pathways at Canaccord Genuity conference: launch path in focus - Investing.com
COMPASS Pathways plc (CMPS) stock price, news, quote and history - Yahoo Finance UK
HC Wainwright Cuts Earnings Estimates for Compass Pathways - MarketBeat
COMPASS Pathways (CMPS) Stock Looks Stretched Following Its 214% One Year Run - Sahm
COMPASS Pathways plc (5Y6.F) stock price, news, quote and history - Yahoo Finance Singapore
Renaissance Technologies LLC Reduces Stock Position in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Compass Pathways partners with VA on psilocybin trial for veterans - Investing.com
Compass Pathfinder Limited: Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin - FinanzNachrichten.de
Compass Pathways (NASDAQ:CMPS) Trading 9.8% HigherWhat's Next? - MarketBeat
Earnings call transcript: COMPASS Pathways advances q2 2026 launch plans as stock slips - Investing.com
COMPASS Pathways Reports Q2 2026 Financials and Updates on COMP360 Clinical Programs - Kalkine Media
Why is Compass Pathways stock rallying today? By Investing.com - Investing.com South Africa
Compass Pathways Q2 Earnings Call Highlights - Yahoo Finance
Seven Fleet Capital Management LP Buys 118,021 Shares of Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
200,000 Shares in Compass Pathways PLC Sponsored ADR $CMPS Acquired by Vivo Capital LLC - MarketBeat
Compass Pathways earnings on deck ahead of pivotal FDA filing - Investing.com
Eversept Partners LP Makes New $3.75 Million Investment in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Orbimed Advisors LLC Buys New Shares in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Affinity Asset Advisors LLC Purchases 908,483 Shares of Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
COMPASS Pathways plc (CMPS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cathie Wood Swaps Robinhood for SpaceX, Archer—Did ARK Pivot Back to Moonshot Innovation? - Sahm
Amova Asset Management Americas Inc. Has $2.03 Million Holdings in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening - Sahm
Compass Pathways (NASDAQ:CMPS) Trading Down 5.5%Here's Why - MarketBeat
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer - Sahm
COMPASS Pathways (CMPS) Is Down 8.6% After Phase 3 Durability Data For COMP360 In TRD - Yahoo Finance
Compass Pathways study shows minimal interaction in psilocybin trials By Investing.com - Investing.com South Africa
Compass Pathways study shows minimal interaction in psilocybin trials - Investing.com
Should COMP360’s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors? - Sahm
Compass Pathways (NASDAQ:CMPS) Shares Gap UpTime to Buy? - MarketBeat
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up - Yahoo Finance
Compass Pathways stock reiterated Buy at H.C. Wainwright after trial data - Investing.com
Compass Pathways Plc Adr Stock (CMPS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):